Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-03-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 美康生物科技股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details board meeting approvals, amounts, investment products, risk controls, and compliance with regulatory requirements. The document is relatively short (3652 characters) and focuses on disclosing the use of idle raised funds for cash management, including approvals and risk measures. It does not contain financial statements or comprehensive financial data, nor is it a full report like an Annual or Interim Report. It is an announcement about financing activities related to the use of raised funds, which fits the category of Capital/Financing Update (CAP).
2023-03-27 Chinese
关于2023年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the year 2023. It includes descriptions of the types of related party transactions, estimated amounts, pricing principles, approvals by the board and supervisory committee, independent directors' opinions, and the rationale for the transactions. It references compliance with Shenzhen Stock Exchange rules and company bylaws. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory disclosure about related party transactions, which is a common type of regulatory filing in Chinese listed companies. It does not fit into categories like earnings release, capital update, or management report. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-03-17 Chinese
独立董事关于第四届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of the company regarding specific matters discussed at the 15th meeting of the 4th board of directors. It covers the use of idle raised funds for temporary liquidity and cash management, and the forecast of related party transactions for 2023. The document references compliance with company law, company articles, and Shenzhen Stock Exchange rules. It is not a full financial report, earnings release, or audit report. It is also not a notice of voting results or a proxy solicitation. The document is a formal board-related opinion on specific agenda items, which fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company governance and financial decisions. The document length is short (2121 characters), and it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-03-17 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 美康生物科技股份有限公司 regarding the use of part of idle raised funds to temporarily supplement working capital. It details the board and supervisory meetings approving the use of idle raised funds, the amount involved, the reasons for the idle funds, and the compliance with regulatory requirements. It includes references to prior approvals, independent directors' opinions, and the sponsor's opinions. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about the use of capital raised through a specific stock issuance. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or management report. It is a capital/financing update related to the use of raised funds. The document length is about 5,263 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the best classification is Capital/Financing Update (CAP).
2023-03-17 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding the use of idle raised funds by a listed company for cash management. It includes specifics about the amount of funds raised, usage, idle reasons, investment purposes, risk control measures, and approvals from the board, supervisory committee, independent directors, and the sponsor. The document references regulatory guidelines and includes formal opinions and signatures. It is not a brief announcement or a simple notification but a comprehensive verification and opinion report on the use of raised funds. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit-related report concerning the use and management of raised funds, including compliance with regulatory requirements and internal controls, but it is not a full annual or interim report. Q1 2023
2023-03-17 Chinese
第四届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 4th Supervisory Board of Meikang Biotechnology Co., Ltd. It details the approval of proposals related to the use of idle raised funds, cash management, and expected related party transactions for 2023. The document includes voting results and references compliance with relevant laws and stock exchange rules. It does not contain financial statements or detailed financial data but rather reports on supervisory board decisions and approvals. The document length is 2040 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about supervisory board resolutions and fund usage approvals, not a full financial report or management report.
2023-03-17 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.